Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
Acq. announced
Director departure
Letter to company
Asset disposition
Appointed director

NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/05/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
08/15/2023 3 Dais Craig (CFO) has filed a Form 3 on NAVIDEA BIOPHARMACEUTICALS, INC.
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Resignation/termination of a director
07/28/2023 8-K Quarterly results
07/17/2023 4 Moss Dana J (Director) has filed a Form 4 on NAVIDEA BIOPHARMACEUTICALS, INC.
Txns: Granted 250,000 shares @ $0
07/17/2023 3 Moss Dana J (Director) has filed a Form 3 on NAVIDEA BIOPHARMACEUTICALS, INC.
07/13/2023 8-K Resignation/termination of a director
Docs: "Press Release"
07/06/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Letter Agreement between Navidea Biopharmaceuticals, Inc. and John K. Scott, Jr",
"Press Release"
07/03/2023 SC 13D/A Scott John K Jr. reports a 75% stake in Navidea Biopharmaceuticals, Inc.
07/03/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
07/03/2023 SC 13G/A Bain Irwin Allen reports a 4.7% stake in Navidea Biopharmaceuticals, Inc.
06/30/2023 SC 13G/A Bain Irwin Allen reports a 4.7% stake in Navidea Biopharmaceuticals, Inc.
06/30/2023 4 Scott John K Jr. (10% Owner) has filed a Form 4 on NAVIDEA BIOPHARMACEUTICALS, INC.
Txns: Granted 12,200,000 shares @ $0.088, valued at $1.1M
06/16/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
06/16/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Second Amendment to Asset Purchase Agreement between Cardinal Health 414, LLC and Navidea Biopharmaceuticals, Inc",
"[email protected]"
06/16/2023 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "Press Release (furnished pursuant to Item 7.01)"
06/16/2023 8-A12G Form 8-A12G - Registration of securities [Section 12(g)]:
06/16/2023 SC 13D/A Scott John K Jr. reports a 52.8% stake in Navidea Biopharmaceuticals, Inc.
06/15/2023 4 Scott John K Jr. (10% Owner) has filed a Form 4 on NAVIDEA BIOPHARMACEUTICALS, INC.
Txns: Disposed of 990 shares @ $0
Granted 11,508,672 shares @ $0
Bought 11,969 options to buy @ $0.104, valued at $1.2k
Converted 11,969 options to buy @ $0.104, valued at $1.2k
06/12/2023 4 Stefanelli Jill (Director) has filed a Form 4 on NAVIDEA BIOPHARMACEUTICALS, INC.
Txns: Granted 250,000 shares @ $0
06/09/2023 3 Stefanelli Jill (Director) has filed a Form 3 on NAVIDEA BIOPHARMACEUTICALS, INC.
05/25/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation ...
Docs: "Certificate of Designation of Preferences, Rights, Limitations and Restrictions of Series J Preferred Stock",
"Stock Purchase Agreement between Navidea Biopharmaceuticals, Inc. and Donald E. Garlikov",
"Stock Purchase Agreement between Navidea Biopharmaceuticals, Inc. and Irwin Bain",
"Press Release"
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/28/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Opinion of Maslon LLP",
"Common Stock Purchase Agreement between Navidea Biopharmaceuticals, Inc. and Keystone Capital Partners, LLC",
"Registration Rights Agreement between Navidea Biopharmaceuticals, Inc. and Keystone Capital Partners, LLC",
"Secured Bridge Note",
"First Amendment to Security Agreement between Navidea Biopharmaceuticals, Inc. and John Kim Scott, Jr",
"[email protected]"
04/28/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
04/13/2023 8-K Quarterly results
03/31/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Separation & Release Agreement effective March 30, 2023 between Navidea Biopharmaceuticals, Inc. and Michael Rosol",
"Consulting Services Agreement effective March 30, 2023 between Navidea Biopharmaceuticals, Inc. and G2G Ventures",
"Press release"
03/27/2023 10-K Annual Report for the period ended December 31, 2022
03/16/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/10/2023 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Financial Statements and Ex...
Docs: "First Amendment to Section 382 Rights Agreement between Navidea Biopharmaceuticals, Inc. and Continental Stock Transfer & Trust Company, LLC"
12/22/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
12/12/2022 8-K Quarterly results
11/30/2022 4/A Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy